Promising results of mid-stage trial of F17464 in schizophrenia

Positive results of a Phase IIa clinical trial FAST (F17464 in Acute Schizophrenia Trial), conducted on the molecule F17464 on patients with an acute episode of schizophrenia were announced today by independent French drugmaker Pierre Fabre.

F17464 is a preferential dopamine D3 receptor antagonist, discovered by Pierre Fabre's research team, which stands out for its innovative mode of action. Following promising initial pharmacology and safety results, F17464 became the subject of a clinical trial program, including the FAST study, designed to evaluate its efficacy and safety versus placebo on patients with an acute episode of schizophrenia.

This six-week multinational trial showed positive results in terms of efficacy and F17464 was well tolerated by patients, with no metabolic syndrome. Thus, targeting preferentially the D3 receptor should make a difference compared to other treatments available today. This novel mechanism could help treat acute psychotic episodes with a lower risk of causing motor or metabolic impairments as well as increase the activation of relevant circuits for the treatment of negative symptoms, based on the outcome of preclinical studies.